The role of transforming growth factor beta in atherosclerosis: Novel insights and future perspectives

Current Opinion in Lipidology

Volumn 13, Issue 5, 2002, Pages 523-529

  Mallat, Ziad ^a   Tedgui, Alain ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Atherosclerosis; Immune mechanisms; Immune tolerance; Inflammation; Plaque rupture

Indexed keywords

CYTOKINE; GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; HELPER CELL; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; ARTERIOSCLEROSIS; BLOOD; INFLAMMATION; METABOLISM; PATHOLOGY;

ANIMALS; ARTERIOSCLEROSIS; HUMANS; INFLAMMATION; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 0036773855     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200210000-00008     Document Type: Review

References (70)

1. Lusis A. Atherosclerosis. Nature 2000; 407:233-241.
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104:365-372.
3. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20:1262-1275.
4. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 2001; 88:998-1003.
5. Mallat Z, Heymes C, Ohan J, et al. Expression of interleukin-10 in advanced human atherosclerotic plaques. Relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999; 19:611-616.
6. Tedgui A, Mallat Z. Apoptosis as a determinant of atherothrombosis. Thromb Haemost 2001; 86:420-426.
7. Oklu R, Hesketh R. The latent transforming growth factor beta binding protein (LTBP) family. Biochem J 2000; 352:601-610.
8. Massagué J, Wotton D. Transcriptional control by the TGF-β/Smad signaling system. EMBO J 2000; 19:1745-1754.
9. Massagué J, Chen YG. Controlling TGF-β signaling. Genes Dev 2000; 14:627-644.
10. Vodovotz Y, Bogdan C, Paik J, et al. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor-β. J Exp Med 1993; 178:605-613.
11. Bogdan C, Nathan C. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann NY Acad Sci 1993; 685:713-739.
12. Gorelik L, Flavell RA. Transforming growth factor-β in T-cell biology. Nat Rev Immunol 2001; 2:46-53.
13. Gorelik L, Fields PE, Flavell RA. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol 2000; 165:4773-4777.
14. Heath VL, Murphy EE, Crain C, et al. TGF-beta1 down-regulates Th2 development and results in decreased IL-4-induced STAT6 activation and GATA-3 expression. Eur J Immunol 2000; 30:2639-2649.
15. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89:587-596.
16. Szabo SJ, Kim ST, Costa GL, et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100:655-669.
17. Mullen AC, High FA, Hutchins AS, et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 2001; 292:1907-1910.
18. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-712.
19. Geissmann F, Revy P, Regnault A, et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 1999; 162:4567-4575.
20. Nandan D, Reiner NE. TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-gamma action. J Immunol 1997; 158:1095-1101.
21. Lee YJ, Han Y, Lu HT, et al. TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J Immunol 1997; 158:2065-2075.
22. Huynh ML, Fadok VA, Henson PM. Phosphalidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002; 109:41-50.
23. Henson PM, Bratton DL, Fadok VA. The phosphatidylserine receptor: a crucial molecular switch? Nat Rev Mol Cell Biol 2001; 2:627-633.
24. Chen W, Frank ME, Jin W, Wahl SM. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001; 14:715-725.
25. Sauter B, Albert ML, Francisco L, et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191:423-434.
26. Huang FP, Platt N, Wykes M, et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med 2000; 191:435-444.
27. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000; 191:411-416.
28. DiChiara MR, Kiely JM, Gimbrone MA, et al. Inhibition of E-selectin gene expression by transforming growth factor β in endothelial cells involves coactivator integration of Smad and nuclear factor kappaB-mediated signals. J Exp Med 2000; 192:695-704.
29. Park SK, Yang WS, Lee SK, et al. TGF-β(1) down-regulates inflammatory cytokine-induced VCAM-1 expression in cultured human glomerular endothelial cells. Nephrol Dial Transplant 2000; 15:596-604.
30. Gamble JR, Bradley S, Noack L, Vadas MA. TGF-β and endothelial cells inhibit vcam-1 expression on human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1995; 15:949-955.
31. Smith WB, Noack L, Khew-Goodall Y, et al. Transforming growth factor-β1 inhibits the production of IL-8 and the transmigration of neutrophils through activated endothelium. J Immunol 1996; 157:360-368.
32. Lefer AM, Tsao P, Aoki N, Palladino MA Jr. Mediation of cardioprotection by transforming growth factor-beta. Science 1990; 249:61-64.
33. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992; 359:693-699.
34. Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993; 90:770-774.
35. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331:1286-1292.
36. Topper JN. TGF-β in the cardiovascular system: molecular mechanisms of a context-specific growth factor. Trends Cardiovasc Med 2000; 10:132-137.
37. Wells RG. Fibrogenesis. V. TGF-beta signaling pathways. Am J Physiol Gastrointest Liver Physiol 2000; 279:G845-G850.
38. Majesky MW, Lindner V, Twardzik DR, et al. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest 1991; 88:904-910.
39. Nikol S, Isner JM, Pickering JG, et al. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest 1992; 90:1582-1592.
40. Schulick AH, Taylor AJ, Zuo W, et al. Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc Natl Acad Sci USA 1998; 95:6983-6988.
41. Smith JD, Bryant SR, Couper LL, et al. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 1999; 84:1212-1222.
42. Grainger DJ, Kemp PR, Liu AC, et al. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370:460-462.
43. Grainger DJ, Mosedale DE, Metcalfe JC, Bottinger EP. Dietary fat and reduced levels of TGFβ1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J Cell Sci 2000; 113:2355-2361.
44. Grainger DJ, Witchell CM, Metcalfe JC. Tamoxifen elevates transforming growth factor-β and suppresses diet-induced formation of lipid lesions in mouse aorta. Nat Med 1995; 1:1067-1073.
45. Lutgens E, Cleutjens KB, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA 2000; 97:7464-7469.
46. McCaffrey TA, Du B, Consigli S, et al. Genomic instability in the type II TGF-β1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest 1997; 100:2182-2188.
47. McCaffrey TA. TGF-βs and TGF-β receptors in atherosclerosis. Cytokine Growth Factor Rev 2000; 11:103-114.
48. Grainger DJ, Kemp BR, Metcalfe JC, et al. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med 1995; 1:74-79.
49. Yokota M, Ichihara S, Lin TL, et al. Association of a T29→C polymorphism of the transforming growth factor-β1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000; 101:2783-2787.
50. Blann AD, Wang JM, Wilson PB, Kumar S. Serum levels of the TGF-β receptor are increased in atherosclerosis. Atherosclerosis 1996; 120:221-226.
51. Wang XL, Liu SX, Wilcken DEL. Circulating transforming growth factor-β1 and coronary artery disease. Cardiovasc Res 1997; 34:404-410.
52. Reckless J, Metcalfe JC, Grainger DJ. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation 1997; 95:1542-1548.
53. Bobik A, Agrotis A, Kanellakis P, et al. Distinct patterns of transforming growth factor-β isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-β in fibrofatty lesion development. Circulation 1999; 99:2883-2891.
54. Williams KJ. Arterial wall chondroitin sulfate proteoglycans: diverse molecules with distinct roles in lipoprotein retention and atherogenesis. Curr Opin Lipidol 2001; 12:477-487.
55. Mallat Z, Gojova A, Marchiol-Fournigault C, et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001; 89:930-934.
56. Lutgens E, Gijbels M, Smook M, et al. Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002; 22:975-982.
57. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417:750-754.
58. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990; 346:281-284.
59. Bottinger EP, Jakubczak JL, Roberts IS, et al. Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas. EMBO J 1997; 16:2621-2633.
60. Cazac BB, Roes J. TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 2000; 13:443-451.
61. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12:2171-2181.
62. Lucas PJ, Kim SJ, Melby SJ, Gress RE. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J Exp Med 2000; 191:1187-1196.
63. Nakao A, Miike S, Hatano M, et al. Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med 2000; 192:151-158.
64. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:1876-1890.
65. Groux H. An overview of regulatory T cells. Microbes Infect 2001; 3:883-889.
66. Weiner HL. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect 2001; 3:947-954.
67. Weiner HL. Oral tolerance, an active immunologic process mediated by multiple mechanisms. J Clin Invest 2000; 106:935-937.
68. Weiner HL. The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat Immunol 2001; 2:671-672.
69. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2:725-731.
70. Groux H, Powrie F. Regulatory T cells and inflammatory bowel disease. Immunol Today 1999; 20:442-445.